SCHEMBL3559671

SCHEMBL3559671

Cc1cc(-c2ccc(C(F)(F)F)cc2)nc(-c2ccnc(Cl)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.55
S1PR3 Q99500 1/20 0.55
SYK P43405 3/20 0.47
TOP1 P11387 3/20 0.43
RAD51 Q06609 1/20 0.42
CNR1 P21554 2/20 0.41
KIF11 P52732 1/20 0.41
IDO1 P14902 1/20 0.39
PIM1 P11309 1/20 0.39
CDK4 P11802 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCND3 P30281 1/20 0.39
MTOR P42345 1/20 0.39
GSK3B P49841 1/20 0.39
CCNA1 P78396 1/20 0.39
PTGS2 P35354 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560497 0.90 S1PR1 (0.59) S1PR1S1PR3TOP1CNR1KIF11
SCHEMBL3556332 0.84 S1PR1 (0.56) S1PR1S1PR3TOP1RAD51CNR1
SCHEMBL3565690 0.84 S1PR1 (0.53) S1PR1S1PR3SYKTOP1CNR1
SCHEMBL1841140 0.83 RAD51 (0.54) SYKTOP1RAD51KIF11ADORA3
SCHEMBL3565439 0.82 SYK (0.42) S1PR1S1PR3SYKTOP1RAD51
SCHEMBL1844483 0.82 RAD51 (0.51) S1PR1S1PR3SYKTOP1RAD51
SCHEMBL7004813 0.81 S1PR1 (0.43) S1PR1S1PR3SYKTOP1RAD51
SCHEMBL3564509 0.81 S1PR1 (0.59) S1PR1S1PR3TOP1KIF11ADORA3
SCHEMBL3285394 0.80 S1PR1 (0.64) S1PR1S1PR3CNR1KIF11IDO1
SCHEMBL3565887 0.78 S1PR1 (0.50) S1PR1S1PR3TOP1CNR1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 S1PR1 1042/4885S1PR3 1066/4885SYK 3521/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 S1PR1 306/4885S1PR3 276/4885SYK 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.